In This Article:
-
Total Revenue: $65 million for Q1 2025, a 63% year-over-year increase after adjusting for a onetime milestone in Q1 2024.
-
US Net Product Revenue: $34.9 million, a 41% year-over-year increase.
-
Royalty Revenue from Daiichi Sankyo Europe: $10.5 million, an 8% increase from Q4 2024.
-
Cash and Cash Equivalents: $114.6 million as of March 31, 2025.
-
Research and Development Expenses: $12.6 million, a 6% decrease from Q1 2024.
-
Selling, General and Administrative Expenses: $43 million, a 2% increase from Q1 2024.
-
Full Year 2025 Operating Expense Guidance: $215 million to $235 million, including $15 million in non-cash stock compensation expenses.
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Esperion Therapeutics Inc (NASDAQ:ESPR) reported a 63% year-over-year growth in total revenue for Q1 2025, reaching $65 million after adjusting for a one-time milestone in Q1 2024.
-
US net product revenue increased by 41% year-over-year to $34.9 million, driven by expanded label and commercial initiatives.
-
The company expanded its field reimbursement support team threefold, enhancing payer access and support for prescribers.
-
NEXLETOL and NEXLIZET were added to the 2025 ACC AHA multi-society guidelines, earning high-level recommendations for patients with acute coronary syndrome.
-
Esperion Therapeutics Inc (NASDAQ:ESPR) is advancing its pipeline with a novel program targeting primary sclerosing cholangitis (PSC), a major unmet need with a $1 billion annual market opportunity.
Negative Points
-
Total revenue decreased by 53% compared to Q1 2024 due to a one-time settlement agreement milestone received in the previous year.
-
The flat lipid market in the US and changes in Medicare Part D impacted Q1 2025 product revenue growth.
-
Collaboration revenue decreased by 73% compared to Q1 2024, primarily due to the absence of the previous year's milestone.
-
Esperion Therapeutics Inc (NASDAQ:ESPR) faced seasonal headwinds with higher out-of-pocket costs for patients due to insurance deductible resets.
-
The company experienced confusion and challenges related to the Inflation Reduction Act and Medicare adjustments, affecting prescription uptake.
Q & A Highlights
Q: When should we expect a new business development (BD) deal, and what is your cash outlook for the remainder of the year? A: (Benjamin Halladay, CFO) We are making good progress on BD deals but are not setting a specific timeline as we want to ensure the right deal is made. These deals are not dependent on the Otsuka milestones. We will execute when the right asset fits our commercial strategy.